Share on StockTwits

Oramed Pharmaceuticals (NASDAQ:ORMP) major shareholder Regals Capital Management Lp purchased 2,252 shares of the company’s stock in a transaction dated Friday, June 6th. The shares were purchased at an average price of $4.44 per share, with a total value of $9,998.88. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Oramed Pharmaceuticals (NASDAQ:ORMP) traded up 10.05% on Tuesday, hitting $9.09. 101,397 shares of the company’s stock traded hands. Oramed Pharmaceuticals has a 1-year low of $5.00 and a 1-year high of $31.73. The stock has a 50-day moving average of $9.48 and a 200-day moving average of $13.05. The company’s market cap is $90.4 million.

Oramed Pharmaceuticals Inc is a development-stage pharmaceutical company. The Company is engaged in the research and development of pharmaceutical solutions, including an orally ingestible insulin capsule or tablet to be used for the treatment of individuals with diabetes, use of orally ingestible capsules, tablets or pills for delivery of other polypeptides.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.